Zurich Cantonal Bank’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-28,680
| Closed | -$1.85M | – | 3329 |
|
|
2025
Q3 | $1.25M | Sell |
28,680
-987
| -3% | -$39.9K | ﹤0.01% | 1148 |
|
|
2025
Q2 | $843K | Buy |
29,667
+3,776
| +15% | +$113K | ﹤0.01% | 1327 |
|
|
2025
Q1 | $764K | Sell |
25,891
-1,568
| -6% | -$48.8K | ﹤0.01% | 1336 |
|
|
2024
Q4 | $799K | Buy |
27,459
+6,089
| +28% | +$254K | ﹤0.01% | 1333 |
|
|
2024
Q3 | $982K | Sell |
21,370
-907
| -4% | -$39.4K | ﹤0.01% | 1135 |
|
|
2024
Q2 | $910K | Buy |
22,277
+7,258
| +48% | +$208K | ﹤0.01% | 1117 |
|
|
2024
Q1 | $383K | Buy |
15,019
+3,551
| +31% | +$55.6K | ﹤0.01% | 1646 |
|
|
2023
Q4 | $104K | Sell |
11,468
-182
| -2% | -$1.22K | ﹤0.01% | 2435 |
|
|
2023
Q3 | $74.3K | Sell |
11,650
-126
| -1% | -$1.09K | ﹤0.01% | 2486 |
|
|
2023
Q2 | $131K | Buy |
11,776
+1,604
| +16% | +$20.1K | ﹤0.01% | 2199 |
|
|
2023
Q1 | $156K | Buy |
10,172
+136
| +1% | +$2.99K | ﹤0.01% | 2033 |
|
|
2022
Q4 | $223K | Buy |
10,036
+4,654
| +86% | +$69.4K | ﹤0.01% | 1757 |
|
|
2022
Q3 | $88K | Hold |
5,382
| – | – | ﹤0.01% | 2325 |
|
|
2022
Q2 | $78K | Sell |
5,382
-100
| -2% | -$1.49K | ﹤0.01% | 2407 |
|
|
2022
Q1 | $101K | Buy |
5,482
+1,304
| +31% | +$22.2K | ﹤0.01% | 2286 |
|
|
2021
Q4 | $99K | Hold |
4,178
| – | – | ﹤0.01% | 2515 |
|
|
2021
Q3 | $103K | Buy |
+4,178
| New | +$90.8K | ﹤0.01% | 2322 |
|
Other funds holding RNAM
Zurich Cantonal Bank's RNAM Position: Q4 2025 in Review
Zurich Cantonal Bank sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 28,680 shares — an estimated $1.85M sold.
Zurich Cantonal Bank first reported a position in RNAM in Q3 2021 and held it in 17 quarters. The position peaked at $1.25M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.
- Zurich Cantonal Bank reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
- Zurich Cantonal Bank sold 28,680 Avidity Biosciences shares in Q4 2025, an estimated $1.85M.
- Zurich Cantonal Bank first reported a position in Avidity Biosciences in Q3 2021 and held it in 17 quarters.
- Zurich Cantonal Bank's Avidity Biosciences position peaked at $1.25M in Q3 2025.
- 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.
Based on Zurich Cantonal Bank's 13F filing for Q4 2025, filed 27 Jan 2026.